- Home
- MANU vs CGON Comparison
MANU vs CGON Comparison
Compare MANU & CGON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MANU
- CGON
- Stock Information
- Founded
- MANU 1878
- CGON 2010
- Country
- MANU United Kingdom
- CGON United States
- Employees
- MANU N/A
- CGON N/A
- Industry
- MANU Services-Misc. Amusement & Recreation
- CGON
- Sector
- MANU Consumer Discretionary
- CGON
- Exchange
- MANU Nasdaq
- CGON NYSE
- Market Cap
- MANU 2.2B
- CGON 2.1B
- IPO Year
- MANU 2012
- CGON 2024
- Fundamental
- Price
- MANU $18.33
- CGON $26.90
- Analyst Decision
- MANU Buy
- CGON Strong Buy
- Analyst Count
- MANU 2
- CGON 10
- Target Price
- MANU $20.75
- CGON $64.44
- AVG Volume (30 Days)
- MANU 469.0K
- CGON 868.1K
- Earning Date
- MANU 06-06-2025
- CGON 08-07-2025
- Dividend Yield
- MANU N/A
- CGON N/A
- EPS Growth
- MANU N/A
- CGON N/A
- EPS
- MANU N/A
- CGON N/A
- Revenue
- MANU $832,748,485.00
- CGON $662,000.00
- Revenue This Year
- MANU $2.44
- CGON N/A
- Revenue Next Year
- MANU $3.26
- CGON $25,206.93
- P/E Ratio
- MANU N/A
- CGON N/A
- Revenue Growth
- MANU N/A
- CGON 224.51
- 52 Week Low
- MANU $12.05
- CGON $14.80
- 52 Week High
- MANU $19.65
- CGON $40.47
- Technical
- Relative Strength Index (RSI)
- MANU 54.95
- CGON 59.29
- Support Level
- MANU $16.67
- CGON $25.51
- Resistance Level
- MANU $19.65
- CGON $27.28
- Average True Range (ATR)
- MANU 0.67
- CGON 1.01
- MACD
- MANU -0.17
- CGON 0.02
- Stochastic Oscillator
- MANU 20.30
- CGON 89.23
About MANU Manchester United Ltd.
Manchester United PLC operates a professional football club together with related and ancillary activities. The company manages the soccer team and all affiliated club activities of the Manchester United Football Club, which includes the media network, foundation, fan zone, news, and sports features, and team merchandise. Manchester United is based in England. The company has three principal sectors from which the majority of the revenue is generated including Commercial, Broadcasting, and Matchday.
About CGON CG ONCOLOGY INC
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.